Effectiveness of Infliximab in Common Variable Immunodeficiency Associated with Enteropathy.

Simple item page
dc.contributor.authorRodrigo Quera
dc.contributor.authorPaulina Núñez
dc.contributor.authorPía Zañartu
dc.contributor.authorLuis Contreras
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T14:58:12Z
dc.date.available2026-03-22T14:58:12Z
dc.date.issued2023
dc.descriptionCitaciones: 3
dc.description.abstractCommon variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults, with non-infectious gastrointestinal involvement present in up to 50 % of patients, with the small intestine and colon being the most affected areas. Reports have evaluated the effectiveness of biologic therapy in this scenario. Here, we describe the clinical, endoscopic, and histological findings of a patient who presented a satisfactory response to infliximab.
dc.identifier.doi10.17235/reed.2023.10032/2023
dc.identifier.urihttps://doi.org/10.17235/reed.2023.10032/2023
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/49617
dc.language.isoen
dc.publisherArán Ediciones
dc.relation.ispartofRevista Española de Enfermedades Digestivas
dc.sourceUniversidad de Los Andes, Chile
dc.subjectCommon variable immunodeficiency
dc.subjectMedicine
dc.subjectInfliximab
dc.subjectEnteropathy
dc.subjectPrimary immunodeficiency
dc.subjectImmunodeficiency
dc.subjectInternal medicine
dc.subjectGastroenterology
dc.subjectHuman immunodeficiency virus (HIV)
dc.subjectImmunology
dc.titleEffectiveness of Infliximab in Common Variable Immunodeficiency Associated with Enteropathy.
dc.typearticle

Files

Collections

Artículo Científico Publicado